Giant Biogene Holding Future Growth
Future criteria checks 4/6
Giant Biogene Holding is forecast to grow earnings and revenue by 16.7% and 17.3% per annum respectively. EPS is expected to grow by 15.5% per annum. Return on equity is forecast to be 29.2% in 3 years.
Key information
16.7%
Earnings growth rate
15.53%
EPS growth rate
| Personal Products earnings growth | 20.1% |
| Revenue growth rate | 17.3% |
| Future return on equity | 29.18% |
| Analyst coverage | Good |
| Last updated | 05 Dec 2025 |
Recent future growth updates
Giant Biogene Holding Co., Ltd. (HKG:2367) Just Reported Earnings, And Analysts Cut Their Target Price
Aug 29
Giant Biogene Holding Co., Ltd. Just Beat Revenue Estimates By 5.3%
Mar 28Recent updates
Giant Biogene Holding Co., Ltd. (HKG:2367) Shares Could Be 31% Below Their Intrinsic Value Estimate
Sep 22Giant Biogene Holding Co., Ltd. (HKG:2367) Just Reported Earnings, And Analysts Cut Their Target Price
Aug 29We Ran A Stock Scan For Earnings Growth And Giant Biogene Holding (HKG:2367) Passed With Ease
Aug 11The Price Is Right For Giant Biogene Holding Co., Ltd. (HKG:2367) Even After Diving 37%
Jun 22Is There An Opportunity With Giant Biogene Holding Co., Ltd.'s (HKG:2367) 33% Undervaluation?
May 29Why Investors Shouldn't Be Surprised By Giant Biogene Holding Co., Ltd.'s (HKG:2367) 29% Share Price Surge
May 07Giant Biogene Holding's (HKG:2367) Solid Earnings May Rest On Weak Foundations
May 06Giant Biogene Holding Co., Ltd. Just Beat Revenue Estimates By 5.3%
Mar 28What Is Giant Biogene Holding Co., Ltd.'s (HKG:2367) Share Price Doing?
Feb 06Here's Why Giant Biogene Holding (HKG:2367) Has Caught The Eye Of Investors
Jan 14Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 9,954 | 3,593 | 2,547 | 3,552 | 19 |
| 12/31/2026 | 8,044 | 2,893 | 2,232 | 2,902 | 21 |
| 12/31/2025 | 6,430 | 2,331 | 1,615 | 2,255 | 19 |
| 6/30/2025 | 6,111 | 2,261 | 1,473 | 1,834 | N/A |
| 3/31/2025 | 5,825 | 2,162 | 1,634 | 1,938 | N/A |
| 12/31/2024 | 5,539 | 2,062 | 1,794 | 2,041 | N/A |
| 9/30/2024 | 4,999 | 1,915 | 1,732 | 1,959 | N/A |
| 6/30/2024 | 4,459 | 1,768 | 1,670 | 1,877 | N/A |
| 3/31/2024 | 3,992 | 1,610 | 1,545 | 1,762 | N/A |
| 12/31/2023 | 3,524 | 1,452 | 1,419 | 1,647 | N/A |
| 9/30/2023 | 3,255 | 1,252 | 1,218 | 1,480 | N/A |
| 6/30/2023 | 2,985 | 1,052 | 1,016 | 1,313 | N/A |
| 3/31/2023 | 2,675 | 874 | 897 | 1,122 | N/A |
| 12/31/2022 | 2,364 | 696 | 778 | 932 | N/A |
| 12/31/2021 | 1,552 | 809 | 617 | 692 | N/A |
| 12/31/2020 | 1,190 | 826 | 758 | 834 | N/A |
| 12/31/2019 | 957 | 552 | 571 | 656 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2367's forecast earnings growth (16.7% per year) is above the savings rate (2.8%).
Earnings vs Market: 2367's earnings (16.7% per year) are forecast to grow faster than the Hong Kong market (12.1% per year).
High Growth Earnings: 2367's earnings are forecast to grow, but not significantly.
Revenue vs Market: 2367's revenue (17.3% per year) is forecast to grow faster than the Hong Kong market (8.5% per year).
High Growth Revenue: 2367's revenue (17.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2367's Return on Equity is forecast to be high in 3 years time (29.2%)
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/06 03:46 |
| End of Day Share Price | 2025/12/05 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Giant Biogene Holding Co., Ltd. is covered by 28 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ethan Cui | BofA Global Research |
| Manqi Huang | China International Capital Corporation Limited |
| Zhuonan Xu | China International Capital Corporation Limited |